Biomarker study for afatinib plus bevacizimab

Biomarker study for afatinib plus bevacizimab - Biomarker study for afatinib plus bevacizimab

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000032489

Enrollment

100

Registered

2018-05-07

Start date

2018-03-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer with EGFR mutations

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients must be enrolled in UMIN000027432

Exclusion criteria

Exclusion criteria: nothing in particular

Design outcomes

Primary

Measure	Time frame
The frequency of development ofEGFR T790M between afatainib arm and afatinib/Bev arm	—

Secondary

Measure	Time frame
The effect of afatiib or afatinib/Bev based on EGFR T790M status The effect of subsequent therapies including osimertinib	—

Countries

Japan

Contacts

Public ContactKadoaki OHASHI

Okayama University Hospital Department of Respiratory Medicine

kohashi@cc.okayama-u.ac.jp086-235-7227

Outcome results